Vifor Pharma AG (SWX:VIFN) agreed to acquire Inositec AG from VI Partners AG and others for CHF 20 million on November 22, 2021. As per the transaction, Vifor Pharma will acquire 100% of the shares in Inositec AG for an upfront payment of CHF 20 million and be eligible for success based clinical earn-out payments in the low triple digit million range. The transaction is expected to occur in Q4 2021.